Algiax Pharmaceuticals Appoints Dr. Ingo Lehrke and Dr. Guido
Koopmans as CEO and CSO. A Proof-of-Concept Study for Neuropathic Pain
is planned to start in Q4 2019.
DÜSSELDORF, Germany–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/koopmans?src=hash" target="_blank"gt;#koopmanslt;/agt;–Algiax Pharmaceuticals, a clinical-stage biotechnology company focused
on development of GABAA receptor modulators for neuropathic
pain and other indications with unmet medical need, announced the
appointment of Dr. Ingo Lehrke as CEO and Dr. Guido Koopmans as CSO,
effective May 1, 2019.
Dr. Lehrke takes over from co-founder and shareholder Dr. Jürgen
Schumacher who becomes chairman of Algiax´ new advisory board. “I am
very happy to have Ingo join and lead our executive team” said Jürgen
Schumacher. “He is an experienced pharma manager and has successfully
developed and partnered a novel pain drug prior to joining Algiax. I
believe that his knowledge will create high added value for the further
development of our lead candidate AP-325.”
Dr. Lehrke served for the last ten years as Managing Director of tesa
Labtec GmbH, a drug delivery company that is part of the Beiersdorf
Group of companies. Before that he was managing director and shareholder
of Labtec GmbH which was acquired by tesa SE in 2008. Dr. Koopmans is
neuroscientist and holds a PhD in Biological Health Science. He
co-founded Algiax Pharmaceuticals and developed AP-325 from bench to
The company further announced that it intends to start a phase IIa
clinical study for its lead candidate AP-325 in chronic neuropathic
pain. “We are excited to initiate the next development stage of AP-325
with the goal to show its proof-of-concept in patients, soon” said Dr.
Koopmans. “We plan to have the first patient included in the fourth
quarter of this year and expect first results in 2020”
About Algiax (www.algiax.com)
Algiax Pharmaceuticals is a clinical-stage biotechnology company
established in 2011. It is dedicated to the discovery and development of
innovative products to treat diseases with a high unmet medical need.
Algiax’ lead candidate AP-325 is a small-molecule GABAA
receptor modulator in clinical development as a therapy for neuropathic
Next to AP-325 Algiax has discovered novel GABAA receptor
modulator compounds called Thioacrylamide (ThAc) derivatives. The
company is advancing a selection of ThAcs derivatives from its discovery
to preclinical characterization.
Ingo Lehrke, CEO
E-mail address: [email protected]